Ornella Addonizio
Psychiatry · Redding, CANPI 1154401149
Payments from drug & device makers
Across 558 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Sunovion Pharmaceuticals Inc.$1K
- Otsuka America Pharmaceutical, Inc.$704
- Teva Pharmaceuticals USA, Inc.$550
- plus $2K from 15 others
What the payments were for
- Food & beverage$8,05498%
- Education$2012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 117 | $1,707 |
| Alkermes, Inc. | 78 | $1,369 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $1,175 |
| Sunovion Pharmaceuticals Inc. | 165 | $1,110 |
| Otsuka America Pharmaceutical, Inc. | 27 | $704 |
| Teva Pharmaceuticals USA, Inc. | 19 | $550 |
| Johnson & Johnson | 12 | $394 |
| Neurocrine Biosciences, Inc. | 16 | $372 |
| Vanda Pharmaceuticals Inc. | 16 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $157 |
| Corium, LLC | 5 | $90 |
| Axsome Therapeutics, Inc. | 3 | $71 |
| Avanir Pharmaceuticals, Inc. | 4 | $68 |
| Neuronetics, Inc. | 2 | $66 |
| Indivior Inc. | 2 | $52 |
| Lundbeck LLC | 2 | $35 |
| Eisai Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,255 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 34 | $264,635 |
| Invega SustennaPaliperidone Palmitate | 33 | $115,175 |
| RexultiBrexpiprazole | 45 | $69,751 |
| CaplytaLumateperone Tosylate | 34 | $58,261 |
| VraylarCariprazine Hcl | 35 | $52,890 |
| LybalviOlanzapine/Samidorphan Malate | 22 | $37,881 |
| FanaptIloperidone | 23 | $37,387 |
| Aripiprazole | 144 | $18,022 |
| Paliperidone ErPaliperidone | 21 | $17,552 |
| Lurasidone Hcl | 88 | $13,061 |
| TrintellixVortioxetine Hydrobromide | 17 | $9,146 |
| LexaproEscitalopram Oxalate | 11 | $4,737 |
| Quetiapine Fumarate | 120 | $4,054 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 55 | $3,947 |
| Divalproex Sodium ErDivalproex Sodium | 42 | $3,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $372 | $264,63534 claims |
| Johnson & JohnsonInvega Sustenna | $394 | $115,17533 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $704 | $69,75145 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,175 | $58,26134 claims |
| AbbVieVraylar, Lexapro | $1,707 | $57,62746 claims |
| Alkermes, Inc.Lybalvi | $1,369 | $37,88122 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $240 | $37,38723 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $157 | $9,14617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Redding
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.